慢性淋巴细胞白血病中单纯绝对淋巴细胞计数进展的发生率与临床影响
该回顾性研究纳入339例2016至2025年间在华盛顿大学/弗雷德·哈钦森癌症中心接受一线治疗的CLL/SLL患者,评估单纯ALC进展(ALC PD)的发生率及影响。结果显示ALC PD在BR治疗中累积发生率高于BTKi和BCL2i,且ALC PD患者从进展起的总生存和至下一治疗或死亡时间均优于其他PD。
要点
- ALC PD的5年OS率为83%,其他PD为56%。
核心结论
- ALC PD可能因治疗方式而异,且与更长的生存和TTNT-D相关。
- 若经更大规模3期数据证实,未来疗效标准或可考虑将ALC PD与其他PD分开报告。
研究设计与样本
- 回顾性研究,纳入339例2016至2025年在华盛顿大学/弗雷德·哈钦森癌症中心连续治疗的CLL/SLL患者。
- 一线治疗包括持续BTKi(n=179)、BR(n=66)和限时BCL2i(n=94)。
主要发现
- ALC PD和其他PD的5年OS率分别为83%和56%。
- 从治疗开始起的OS:未进展者最长,ALC PD居中(HR=3.62;95%CI 1.48-8.85),其他PD最差(HR=11.7;95%CI 5.99-22.9)。
临床怎么用
- 临床中可关注ALC PD这一进展模式,其预后优于其他PD。
- 不同治疗方式下ALC PD发生率不同,BR治疗者需注意监测。
局限性
- 回顾性研究,样本来自单中心,结论需更大规模3期数据验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An increase in the absolute lymphocyte count (ALC) is a component of progressive disease (PD) in chronic lymphocytic leukemia (CLL) and contributes to progression-free survival in phase 3 trials. Prior studies with chemoimmunotherapy demonstrated that PD by ALC alone (ALC PD) conferred better outcomes than other modalities of PD (other PD). To evaluate the incidence and impact of ALC PD with modern treatments, we retrospectively examined 339 consecutive patients with CLL/small lymphocytic lymphoma treated between 2016 and 2025 at the University of Washington/Fred Hutchinson Cancer Center. Patients received frontline therapy with continuous Bruton tyrosine kinase inhibitors (BTKi; n = 179), bendamustine-rituximab (BR; n = 66), and time-limited B-cell lymphoma 2 inhibitors (BCL2i; n = 94). The cumulative incidence of ALC PD was higher with BR than BTKi and BCL2i (P = .021). Across treatment groups, overall survival (OS) from progression was longer for ALC PD than other PD (median, 116 vs 71 months; P = .0012; hazard ratio [HR], 3.15; 95% confidence interval [CI], 1.52-6.53), with 5-year OS rates of 83% and 56%, respectively. Time to next treatment or death (TTNT-D) was longer for ALC PD (median, 14 vs 2.2 months; P< .0001). OS from treatment initiation was longest for nonprogressors, intermediate for ALC PD (HR, 3.62; 95% CI, 1.48-8.85), and worst for other PD (HR, 11.7; 95% CI, 5.99-22.9). These findings suggest that ALC PD may vary based on treatment modality and is associated with longer survival and TTNT-D. If confirmed in larger phase 3 data sets, future response criteria may consider reporting ALC PD separately from other PD.
引用
- Wu X, Shadman M, Voutsinas J, et al. Incidence and clinical impact of absolute lymphocyte count-only progression in chronic lymphocytic leukemia. Blood Adv. 2026. PMID: 42466974. doi:10.1182/bloodadvances.2026020680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。